週三，醫藥巨頭禮來（LLY）股價飆升超10%，市值增長近千億美元。此前該公司發佈的季度財報遠超市場預期，其糖尿病和肥胖症治療藥物Mounjaro與Zepbound銷售表現尤為亮眼。 財報顯示，禮來第四季度營收同比增長43%，達到193億美元。其中，GLP-1類藥物Mounjaro和Zepbound銷售額分別激增110%和123%，達到74億美元和43億美元，成為推動業績增長的核心動力。
On Wednesday, the stock price of pharmaceutical giant Eli Lilly (LLY) surged by over 10%, boosting its market capitalization by nearly $100 billion. This followed the company’s quarterly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results